76
Participants
Start Date
October 12, 2022
Primary Completion Date
March 11, 2025
Study Completion Date
March 11, 2025
remibrutinib
oral tablets
placebo
oral tablets
Columbia University Irving Medical, New York
Childrens National Hospital, Washington D.C.
Institute for Asthma and Allergy PC, Chevy Chase
Johns Hopkins Hospital, Baltimore
Allervie Clinical Research, Birmingham
Family Allergy and Asthma, Louisville
Bluegrass Allergy Research ., Lexington
CR Services Acquisition US Main center, Columbus
University of Michigan Clinical Trials Office, Ann Arbor
Asthma and Allergy Center of Chicago S C, River Forest
Midwest Allergy Sinus Asthma SC, Normal
Arkansas Children's Hospital, Little Rock
Vital Prospects Clinical Research Institute, Tulsa
Western Sky Medical Research, El Paso
Colorado Allergy and Asthma Ctr PC, Denver
Asthma and Allergy Associates P C, Colorado Springs
Treasure Valley Medical Research, Boise
Allergy Associates of Utah, Sandy City
California Allergy and Asthma Medical Group, Los Angeles
Allergy and Asthma Clin Res Inc, Walnut Creek
Seattle Allergy and Asthma Rsch, Seattle
Massachusetts General Hospital, Boston
CenExel HRI, Berlin
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY